drugset / Trial / NCT07455617
Study of ABO2102 in KRAS-Mutated Solid Tumors
Phase 1
Recruiting
101 enrolled
Suzhou Abogen Biosciences Co., Ltd.
Abogen Biosciences (Shanghai) Co., Ltd · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, open-label Phase 1 clinical study to evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics, as well as preliminary anti-tumor activity of ABO2102 as monotherapy and in combination among participants with solid tumors with KRAS mutations.
Timeline
- Start
- 2026-03-24
- Primary completion
- 2029-06
- Completion
- 2030-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABO2102 | Messenger RNA (mRNA) | — | Intramuscular |
| Subject | Sintilimab | Monoclonal antibody | — | Intravenous |